Sputum Microbiome and Chronic Obstructive Pulmonary Disease in a Rural Ugandan Cohort of Well-Controlled HIV InfectionOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
Researchers examined the sputum microbiome in 200 rural Ugandan adults, stratified by HIV status and COPD, to understand respiratory microbial patterns in people living with HIV on antiretroviral therapy.
How was it studied?
Induced sputum samples underwent 16S rRNA gene sequencing, with PICRUSt2 used to predict functional pathways. A statistical model adjusted for confounders including antiretroviral therapy, age, and sex.
What did they find?
Three distinct microbial community types emerged, and their distribution differed significantly by HIV status. Veillonella, Actinomyces, Atopobium, and Filifactor were enriched in HIV-infected individuals, while COPD status tracked with Gammaproteobacteria and Selenomonas abundance. HIV-COPD comorbidity showed reduced bacterial richness and significant Campylobacter enrichment, and HIV-positive patients showed depleted glutamate degradation pathway capacity.
Why it matters
Even with viral suppression via antiretroviral therapy, sputum microbiota remained altered in people living with HIV, suggesting the respiratory microbiome could inform COPD risk stratification in this population.